The European Medicines Agency is now reviewing the safety of using dual renin-angiotensin system blockade in clinical practice because of concerns of hyperkalemia, low blood pressure, and kidney...

For complete story visit theheart.org.

The controversy continues over the cardiovascular side effects of both long-acting beta-agonist and long-acting anticholinergic drugs when newly prescribed for the management of chronic obstructive...

For complete story visit theheart.org.

Hatha yoga introduced to individuals with hypertension appears to lower blood pressure, and while the reductions in blood pressure aren't earth-shattering, they might just be enough to avoid starting...

For complete story visit theheart.org.

New data from the Symplicity HTN-2 study confirm the long-term efficacy of renal denervation in patients with resistant hypertension. At 30 months, there was a sustained reduction in systolic blood...

For complete story visit theheart.org.

It calls for a reappraisal of health recommendations that focus on cutting saturated-fat intake levels, as "mechanisms for adverse health effects are lacking."

For complete story visit theheart.org.

A new analysis of BARBER-1 suggests that physician inertia might be the reason African American men failed to reduce their blood pressure lower than hoped.

For complete story visit theheart.org.

If you don't use it, you're going to lose it—the old chestnut is supported by a new VA Medical Center study showing that fit elderly patients with hypertension had a lower risk of death than...

For complete story visit theheart.org.

The EMA has issued a recommendation that the benefits of the hormonal acne treatment Diane and its generics outweigh the risks, provided that several measures are taken to minimize the risk of...

For complete story visit theheart.org.

A survey of the society's physician members shows there is wide support for, although also some concerns about, the practice, which remains controversial in the US.

For complete story visit theheart.org.

Mahaffey is the second Duke physician to head to Stanford in the past two years, following in the footsteps of Dr Robert Harrington.

For complete story visit theheart.org.